Alaunos Therapeutics Statistics
Total Valuation
TCRT has a market cap or net worth of $6.76 million. The enterprise value is $5.67 million.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, before market open.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TCRT has 1.60 million shares outstanding. The number of shares has increased by 0.11% in one year.
| Current Share Class | 1.60M |
| Shares Outstanding | 1.60M |
| Shares Change (YoY) | +0.11% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 4.16% |
| Owned by Institutions (%) | 9.19% |
| Float | 1.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 675.73 |
| Forward PS | n/a |
| PB Ratio | 3.28 |
| P/TBV Ratio | 3.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 566.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.98
| Current Ratio | 3.98 |
| Quick Ratio | 1.58 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -111.80% and return on invested capital (ROIC) is -71.86%.
| Return on Equity (ROE) | -111.80% |
| Return on Assets (ROA) | -54.59% |
| Return on Invested Capital (ROIC) | -71.86% |
| Return on Capital Employed (ROCE) | -233.25% |
| Revenue Per Employee | $10,000 |
| Profits Per Employee | -$4.68M |
| Employee Count | 1 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.02% in the last 52 weeks. The beta is -0.53, so TCRT's price volatility has been lower than the market average.
| Beta (5Y) | -0.53 |
| 52-Week Price Change | -76.02% |
| 50-Day Moving Average | 1.68 |
| 200-Day Moving Average | 2.73 |
| Relative Strength Index (RSI) | 90.85 |
| Average Volume (20 Days) | 1,282,281 |
Short Selling Information
The latest short interest is 51,732, so 3.23% of the outstanding shares have been sold short.
| Short Interest | 51,732 |
| Short Previous Month | 59,065 |
| Short % of Shares Out | 3.23% |
| Short % of Float | 3.37% |
| Short Ratio (days to cover) | 5.18 |
Income Statement
In the last 12 months, TCRT had revenue of $10,000 and -$4.68 million in losses. Loss per share was -$2.92.
| Revenue | 10,000 |
| Gross Profit | 10,000 |
| Operating Income | -4.81M |
| Pretax Income | -26.77M |
| Net Income | -4.68M |
| EBITDA | -4.81M |
| EBIT | -4.81M |
| Loss Per Share | -$2.92 |
Full Income StatementBalance Sheet
The company has $1.09 million in cash and n/a in debt, giving a net cash position of $1.09 million or $0.68 per share.
| Cash & Cash Equivalents | 1.09M |
| Total Debt | n/a |
| Net Cash | 1.09M |
| Net Cash Per Share | $0.68 |
| Equity (Book Value) | 2.06M |
| Book Value Per Share | 1.29 |
| Working Capital | 2.06M |
Full Balance SheetCash Flow
| Operating Cash Flow | -4.97M |
| Capital Expenditures | n/a |
| Free Cash Flow | -4.97M |
| FCF Per Share | -$3.10 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -48,120.00% |
| Pretax Margin | -46,790.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |